MDAI vs PACB
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 22, 2026
MDAI
51.7
AI Score
VS
MDAI Wins
PACB
44.3
AI Score
Investment Advisor Scores
PACB
44score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | MDAI | PACB | Winner |
|---|---|---|---|
| Revenue | 7.51M | 76.19M | PACB |
| Net Income | -7.59M | -53.02M | MDAI |
| Gross Margin | 41.8% | 33.4% | MDAI |
| Net Margin | -101.0% | -69.6% | PACB |
| Operating Income | -6.29M | -52.97M | MDAI |
| ROE | 63.0% | 159.6% | PACB |
| ROA | -39.0% | -7.1% | PACB |
| Total Assets | 19.44M | 751.85M | PACB |
| Cash | 14.00M | 61.00M | PACB |
| Current Ratio | 0.90 | 4.92 | PACB |
Relative Price Performance (Last 90 Days)
MDAI 1M: -11.1%
· 3M: -12.2%
PACB 1M: +33.5%
· 3M: +55.1%
Current Technical Phase
MDAI
MarkdownSell / avoid
Price below a falling SMA50 (slope -1.4%), weak momentum, RSI 29
PACB
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (25.9% over 20 days), RSI 55
Fundamentals Snapshot
| Metric | MDAI | PACB |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -4.7 | -5.0 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.3% | 0.0% |
| Gross Margin | 0.4% | 0.3% |
| Operating Margin | -1.2% | -1.1% |
| EPS | -0.32 | -0.41 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, MDAI is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.